Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Capecitabine in Refractory HER2+ Metastatic Breast Cancer
NCT00107393Phase 2Completed
- Sponsor
- Tohoku University
- Start
- Jun 2003
- Primary completion
- May 2008
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and capecitabine in breast cancer, sponsored by Tohoku University. Primary endpoints: Median Survival Time at 2 years and 2-Year Survival Rate. Started Jun 2003; status: completed.
02
Drugs
trastuzumabcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00107393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00107393.